Craig Hettenbach

Q: What is Craig Hettenbach's success rate?

Craig Hettenbach currently has a success rate of 89.28504385889029.

Q: What is the average return of Craig Hettenbach's calls?

Their stock ratings have generated an average return of 20.54445078330056.

Morgan Stanley | Healthcare

Craig Hettenbach is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1454 out of 4673 analysts, they have issued 17 stock ratings with a success rate of 89.29% and an average return of 20.54%.

With 17 ratings to date, Craig Hettenbach is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 89.29% and an average return of 20.54%, highlighting promising potential as their track record develops further.

#1454

Out of 4673

Total Ratings

+89.29%

Success Rate

+20.54%

Average Return

Recent Ratings Analysis

GMRS

Hold

Jun 08, 2026

Target

$14.00

Current

$10.58

Performance

0.00%

Craig Hettenbach rated GMRS as Equal-Weight on Jun 08, 2026, setting a price target of 14. The Hold stance appears justified, as shares hovered around 10.58 with a 0.00% move.

AMWL

Hold

May 06, 2026

Target

$6.50

Current

$8.75

Performance

22.38%

On May 06, 2026, AMWL was given a Equal-Weight rating by Craig Hettenbach, with a target price of 6.5. The stock rallied from 8.75 to 8.75 after the Hold rating, surprising to the upside.

WAY

Hold

Mar 30, 2026

Target

$28.00

Current

$18.98

Performance

-19.10%

WAY received a Equal-Weight rating from Craig Hettenbach on Mar 30, 2026, aiming for 28. The Hold stance proved prudent, with the market softening by 19.10%.

OMDA

Buy

Mar 06, 2026

Target

$32.00

Current

$17.88

Performance

27.26%

On Mar 06, 2026, Craig Hettenbach published a Overweight outlook on OMDA, with a target of 32. Shares gained 27.26%, underscoring the accuracy of the bullish outlook toward 32.

VEEV

Hold

Mar 05, 2026

Target

$215.00

Current

$167.24

Performance

—

Craig Hettenbach on Mar 05, 2026 assigned VEEV a Equal-Weight rating, with a price target of 215. The Hold stance reflected consolidation, as shares held near 167.24.

HIMS

Hold

Feb 25, 2026

Target

$40.00

Current

$27.17

Performance

71.74%

On Feb 25, 2026, Craig Hettenbach reaffirmed HIMS with a Equal-Weight rating, targeting 40. Market strength beyond 27.17 went further than the conservative outlook suggested.

GDRX

Hold

Dec 18, 2025

Target

$5.00

Current

$2.63

Performance

—

GDRX was rated Equal-Weight by Craig Hettenbach on Dec 18, 2025, with a price objective of 5. Flat performance suggests the Hold view was reasonable.

HCA

Sell

Dec 15, 2025

Target

$425.00

Current

$361.32

Performance

-24.25%

On Dec 15, 2025, Craig Hettenbach initiated coverage on HCA with a Underweight rating and target of 425. Shares gained despite the bearish call, moving higher from 361.32.

ARDT

Hold

Nov 14, 2025

Target

$12.00

Current

$8.83

Performance

-2.00%

Craig Hettenbach issued a Equal-Weight recommendation for ARDT on Nov 14, 2025, price target set at 12. The rating was appropriate for a consolidating market trading near 8.83.

HNGE

Buy

Sep 23, 2025

Target

$67.00

Current

$62.86

Performance

5.40%

On Sep 23, 2025, HNGE was evaluated by Craig Hettenbach, who gave a Overweight rating and target of 67. This case illustrates how a timely bullish rating can translate into tangible gains of 5.40%.

SLAB

Hold

Aug 06, 2025

Target

$144.00

Current

$218.20

Performance

76.31%

Craig Hettenbach rated SLAB as Equal-Weight on Aug 06, 2025, setting a price target of 144. Despite the Hold call, shares climbed 76.31% to 218.2, revealing unexpected momentum.

UHS

Hold

Mar 26, 2025

Target

$200.00

Current

$142.87

Performance

-22.55%

On Mar 26, 2025, UHS was given a Equal-Weight rating by Craig Hettenbach, with a target price of 200. The rating provided protection from downside risk as the stock fell to 142.87.

THC

Buy

Mar 26, 2025

Target

$165.00

Current

$163.01

Performance

22.53%

THC received a Overweight rating from Craig Hettenbach on Mar 26, 2025, aiming for 165. Momentum has favored the Buy call, with shares climbing from 163.01 to 163.01, rewarding those who trusted the recommendation.

RCM

Buy

Jul 08, 2024

Target

$17.00

Current

$14.31

Performance

13.03%

On Jul 08, 2024, Craig Hettenbach published a Overweight outlook on RCM, with a target of 17. Shares gained 13.03%, underscoring the accuracy of the bullish outlook toward 17.

SHCR

Hold

Jun 24, 2024

Target

$1.43

Current

$1.43

Performance

4.38%

Craig Hettenbach on Jun 24, 2024 assigned SHCR a Equal-Weight rating, with a price target of 1.43. The Hold stance reflected consolidation, as shares held near 1.43.

DH

Hold

May 08, 2024

Target

$9.00

Current

$0.85

Performance

-84.18%

On May 08, 2024, Craig Hettenbach reaffirmed DH with a Equal-Weight rating, targeting 9. The Hold stance reflected market caution that was later justified.

Frequency Asked Questions

Who is Craig Hettenbach?

Craig Hettenbach is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Craig Hettenbach's success rate?

Craig Hettenbach currently has a success rate of +89.29%.

How many ratings has Craig Hettenbach issued?

Craig Hettenbach has issued 17 stock ratings so far.

What is the average return of Craig Hettenbach's calls?

Their stock ratings have generated an average return of +20.54%.

What is Craig Hettenbach's ranking?

Craig Hettenbach is ranked #1454 out of 4673 analysts.

What types of ratings does Craig Hettenbach give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Craig Hettenbach?

You can follow Craig Hettenbach by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Craig Hettenbach?

Their latest rating was a Hold on GMRS issued on 2026-06-08.